<DOC>
	<DOCNO>NCT00866658</DOCNO>
	<brief_summary>The purpose study evaluate benefit risk lixisenatide ( AVE0010 ) , comparison placebo , add-on treatment basal insulin without sulfonylurea , period 24 week treatment . The primary objective ass effect lixisenatide , add basal insulin , glycemic control term glycosylated hemoglobin ( HbA1c ) reduction Week 24 . The secondary objective assess effect lixisenatide body weight , 2-hour postprandial plasma glucose ( PPG ) standardize meal challenge test , percentage patient reach HbA1c le 7 percent ( % ) , percentage patient reach HbA1c le equal 6.5 % , fast plasma glucose ( FPG ) , change 7-point self-monitored plasma glucose ( SMPG ) profile , change daily basal insulin total insulin dos ; evaluate safety , tolerability , pharmacokinetics ( PK ) , anti-lixisenatide antibody development .</brief_summary>
	<brief_title>GLP-1 Receptor Agonist Lixisenatide Patients With Type 2 Diabetes Glycemic Control Safety Evaluation , Top Basal Insulin +/- Sulfonylurea ( GETGOAL-L-ASIA )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 2 diabetes mellitus , diagnose least 1 year time screen visit , insufficiently control basal insulin without sulfonylurea HbA1c le ( &lt; ) 7 percent ( % ) great ( &gt; ) 10 % screen At time screen age &lt; legal age majority Pregnant breastfeed woman woman childbearing potential effective contraceptive method Type 1 diabetes mellitus Treatment basal insulin le 3 month prior screen insulin regimen change last 3 month prior screen Basal insulin dose screen &lt; 10 units/day and/or last 2 month dose stable ( +/ 20 % ) Sulfonylurea stable ( unchanged ) dose least 3 month prior screen FPG screen &gt; 250 milligram/deciliter ( mg/dL ) ( &gt; 13.9 millimole/liter [ mmol/L ] ) History hypoglycemia unawareness Weight change 5 kilogram ( kg ) 3 month precede screen visit History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease History metabolic acidosis , include diabetic ketoacidosis within 1 year prior screen Hemoglobinopathy hemolytic anemia , receipt blood plasma product within 3 month prior time screen Within last 6 month prior screen : history myocardial infarction , stroke , heart failure require hospitalization Known history drug alcohol abuse within 6 month prior time screen Cardiovascular , hepatic , neurological , endocrine disease , active malignant tumor major systemic disease patient short life expectancy make implementation protocol interpretation study result difficult , history presence clinically significant diabetic retinopathy , history presence macular edema likely require laser treatment within study period Uncontrolled inadequately control hypertension time screen rest systolic blood pressure diastolic blood pressure &gt; 180 millimeter mercury ( mmHg ) &gt; 95 mmHg , respectively Laboratory finding time screening : aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase : &gt; 2 time upper limit normal ( ULN ) laboratory range ; amylase and/or lipase : &gt; 3 time ULN ; total bilirubin : &gt; 1.5 time ULN ( except case Gilbert 's syndrome ) ; hemoglobin &lt; 11 gram/deciliter and/or neutrophil &lt; 1500 per cubic millimeter ( mm^3 ) and/or platelet &lt; 100 000/mm^3 ; positive test Hepatitis B surface antigen and/or Hepatitis C antibody positive serum pregnancy test female childbearing potential Any clinically significant abnormality identify physical examination , laboratory test , electrocardiogram , vital sign time screen , judgment investigator subinvestigator , preclude safe completion study constrain efficacy assessment Patients consider investigator inappropriate study reason ( example , impossibility meet specific protocol requirement , schedule visit , able selfinjections , likelihood require treatment screen phase treatment phase drug permit clinical study protocol ) Patient investigator subinvestigator , pharmacist , study coordinator , study staff relative thereof directly involve conduct protocol Use oral injectable antidiabetic hypoglycemic agent sulfonylurea basal insulin ( example , metformin , alpha glucosidase inhibitor , thiazolidinedione , rimonabant , exenatide , dipeptidyl peptidase 4 inhibitor , fast act insulin 1 week etc . ) within 3 month prior time screen Use systemic glucocorticoid ( exclude topical application inhale form ) 1 week within 3 month prior time screen Use investigational drug within 3 month prior screen Participation previous study lixisenatide Endstage renal disease define serum creatinine clearance &lt; 15 milliliter/minute ( mL/min ) ( calculate Cockcroft Gault formula ) and/or patient dialysis Clinically relevant history gastrointestinal disease associate prolonged nausea vomiting , include , limited gastroparesis gastroesophageal reflux disease require medical treatment , within 6 month prior time screen Allergic reaction glucagon like peptide1 ( GLP1 ) agonist past ( example , exenatide , liraglutide ) metacresol Additional exclusion criterion end runin phase : informed consent withdrawal ; lack compliance singleblind placebo runin phase ( &gt; 2 injection miss ) ; patient adverse event could preclude inclusion study , assess investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>hyperglycemia</keyword>
	<keyword>GLP-1</keyword>
	<keyword>sulfonylurea</keyword>
	<keyword>insulin</keyword>
</DOC>